OpenLobby.EU
Explore

AbbVie

ABBV

AbbVie is a global research-based biopharmaceutical company focused on developing treatments for serious health conditions.

Lobbying Activity

Meeting with Jutta Paulus (Member of the European Parliament)

6 Jan 2026 · Standortbesuch

Meeting with Ondřej Knotek (Member of the European Parliament, Shadow rapporteur)

17 Nov 2025 · Critical Medicines Act

Meeting with Michalis Hadjipantela (Member of the European Parliament)

3 Nov 2025 · Meeting about Critical Medicines Act and Biotech Act

Meeting with Stefan Köhler (Member of the European Parliament)

16 Oct 2025 · Politischer Austausch zur UWWTD

Meeting with Ingeborg Ter Laak (Member of the European Parliament)

16 Oct 2025 · CMA and Biotech Act

Meeting with Sirpa Pietikäinen (Member of the European Parliament)

16 Oct 2025 · EU initiatives in health

Meeting with Michael Mcnamara (Member of the European Parliament)

16 Oct 2025 · Biotech Act

Meeting with Michele Picaro (Member of the European Parliament, Rapporteur for opinion)

15 Oct 2025 · Pharmaceuticals

Meeting with Pietro Fiocchi (Member of the European Parliament)

15 Oct 2025 · Tematiche salute

Meeting with Jutta Paulus (Member of the European Parliament)

15 Oct 2025 · Pharmaceuticals

Meeting with Andreas Glück (Member of the European Parliament, Shadow rapporteur for opinion)

15 Oct 2025 · CMA

Meeting with Nicola Zingaretti (Member of the European Parliament)

15 Oct 2025 · Biotech Act

Meeting with Eero Heinäluoma (Member of the European Parliament)

15 Oct 2025 · Competitiveness, innovation, incl. Biotech Act

Meeting with Nina Carberry (Member of the European Parliament)

15 Oct 2025 · Trade Policy & Health Policy

Meeting with Laura Ballarín Cereza (Member of the European Parliament)

15 Oct 2025 · Health Policies

Meeting with Jeannette Baljeu (Member of the European Parliament)

15 Oct 2025 · Critical Medicines Act

Meeting with Margarita De La Pisa Carrión (Member of the European Parliament)

2 Oct 2025 · Pharma Package

Meeting with Aurelijus Veryga (Member of the European Parliament)

3 Sept 2025 · Discussion on Critical Medicines Act amendments

Meeting with András Tivadar Kulja (Member of the European Parliament, Shadow rapporteur for opinion)

1 Sept 2025 · CMA

Meeting with András Tivadar Kulja (Member of the European Parliament, Shadow rapporteur for opinion)

10 Jul 2025 · Critical medicines act

Meeting with Jessica Polfjärd (Member of the European Parliament)

11 Jun 2025 · Health Policy

Meeting with Vytenis Povilas Andriukaitis (Member of the European Parliament)

5 Jun 2025 · Parkinson’s care in Europe

Meeting with Michalis Hadjipantela (Member of the European Parliament)

25 Mar 2025 · Introductory Meeting

Meeting with Billy Kelleher (Member of the European Parliament)

25 Mar 2025 · Critical Medicines Act, Pharma legislation, trade, BioTech Act

Meeting with Sirpa Pietikäinen (Member of the European Parliament)

25 Mar 2025 · Migraine and women's health

Meeting with Niels Geuking (Member of the European Parliament)

18 Dec 2024 · Herzgesundheit

Meeting with Joanna Scheuring-Wielgus (Member of the European Parliament)

18 Dec 2024 · Women's Health and Unmet Medical Needs – Migraine, Menopause, and Other Challenges

Meeting with Vlad Vasile-Voiculescu (Member of the European Parliament)

18 Dec 2024 · Introductory Meeting

Meeting with Oliver Schenk (Member of the European Parliament)

21 Nov 2024 · Innovative Solutions to the European Health Systems

Meeting with Tomislav Sokol (Member of the European Parliament) and Affordable Medicines Europe and

17 Oct 2024 · Health policy

AbbVie urges greater developer involvement in EU clinical assessments

29 Mar 2024
Topic — Establishing implementing rules for joint clinical assessments of medicinal products across Europe.
Message — AbbVie requests strengthening the involvement of health technology developers throughout the scoping process. They advocate for extending dossier preparation timelines to at least four and a half months. They also suggest longer deadlines for identifying technical inaccuracies in assessment reports.123
Why — Extended timelines and earlier visibility would help the company submit high-quality dossiers.4
Read full response

Meeting with Nikos Papandreou (Member of the European Parliament)

28 Feb 2024 · Review of pharmaceutical legislation

Meeting with Andreas Glück (Member of the European Parliament)

19 Feb 2024 · Pharmapaket

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur) and Haleon and Pharma Deutschland e.V

14 Feb 2024 · Directive on Medicinal products for human use

Meeting with Nathalie Colin-Oesterlé (Member of the European Parliament)

13 Feb 2024 · Législation pharmaceutique

Meeting with Ondřej Knotek (Member of the European Parliament)

7 Feb 2024 · Pharmaceutical package

Meeting with Cristian-Silviu Buşoi (Member of the European Parliament)

6 Feb 2024 · pharmaceutical legislation

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur)

25 Jan 2024 · Directive on Medicinal products for human use

Meeting with Laura Ballarín Cereza (Member of the European Parliament, Shadow rapporteur for opinion) and American Chamber of Commerce to the European Union and

23 Jan 2024 · Pharmaceutical Package (Regulation)

Meeting with Peter Liese (Member of the European Parliament) and European Federation of Pharmaceutical Industries and Associations and Deutscher Caritasverband e. V.

22 Jan 2024 · Austausch

Meeting with Tiemo Wölken (Member of the European Parliament, Rapporteur) and A. Menarini Industrie Farmaceutiche Riunite s.r.l.

18 Dec 2023 · Revision of Pharmaceutical Package (staff level)

Meeting with Pascal Arimont (Member of the European Parliament) and RPP Group

13 Dec 2023 · Revision of Pharmaceutical Legislation

Meeting with Frédérique Ries (Member of the European Parliament, Shadow rapporteur)

12 Dec 2023 · Revision of the Pharmaceutical Legislation

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur) and Platform for Better Oral Health in Europe

7 Dec 2023 · Directive on Medicinal products for human use

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur)

31 Oct 2023 · Directive on Medicinal products for human use

Meeting with Erik Poulsen (Member of the European Parliament) and European Federation of Pharmaceutical Industries and Associations and GSK

30 Oct 2023 · Pharmaceuticals legislation

Meeting with Andrey Slabakov (Member of the European Parliament, Shadow rapporteur)

25 Oct 2023 · Reform of the EU pharmaceutical legislation

Meeting with Tomislav Sokol (Member of the European Parliament, Shadow rapporteur) and European Society of Cardiology and

25 Oct 2023 · Pharmaceutical legislation

Meeting with Mairead McGuinness (Commissioner) and

21 Sept 2023 · Discussions covered AbbVie’s presence in Europe including 5 major sites in Ireland; the sector’s demand for skills and training; the pharmaceutical strategy for Europe and access to medicine in Ireland.

Meeting with Tiemo Wölken (Member of the European Parliament, Rapporteur) and European Federation of Pharmaceutical Industries and Associations and

7 Sept 2023 · Revision of the Pharmaceutical Legislation (staff level)

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur) and Novartis International AG and

18 Jul 2023 · Directive on Medicinal products for human use

Meeting with Pascal Arimont (Member of the European Parliament)

12 Jul 2023 · Reform of the EU pharmaceutical legislation

Meeting with Tiemo Wölken (Member of the European Parliament, Rapporteur) and Bundesverband der Pharmazeutischen Industrie e.V.

28 Jun 2023 · Revision of Pharmaceutical Legislation (staff level)

Meeting with Deirdre Clune (Member of the European Parliament)

23 Jun 2023 · Launch of STEM project

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur) and European Federation of Pharmaceutical Industries and Associations

13 Jun 2023 · Directive on Medicinal products for human use

Meeting with Elina Melngaile (Cabinet of Executive Vice-President Valdis Dombrovskis), Zaneta Vegnere (Cabinet of Executive Vice-President Valdis Dombrovskis) and

5 Jun 2023 · Trade & Technology Council, Global Steel and Aluminum Arrangement, Critical Minerals Agreement

Meeting with Nicola Beer (Member of the European Parliament) and Amazon Europe Core SARL and Vodafone Belgium SA

27 May 2023 · Exhange of views

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur)

23 May 2023 · Medicinal products for human use

Meeting with Valérie Hayer (Member of the European Parliament)

25 Apr 2023 · Industrial sector and strategic autonomy

Meeting with Vlad-Marius Botoş (Member of the European Parliament)

23 Feb 2023 · A pharmaceutical strategy for Europe

Meeting with Pascal Arimont (Member of the European Parliament) and RPP Group

16 Feb 2023 · Pharmaceutical Innovation and European Strategic Autonomy

Meeting with Klemen Grošelj (Member of the European Parliament)

15 Feb 2023 · Europe´s open strategic autonomy

Meeting with Lara Wolters (Member of the European Parliament, Rapporteur)

8 Feb 2023 · Meeting due diligence directive

Meeting with Frédérique Ries (Member of the European Parliament)

11 Jan 2023 · Maintenir l'innovation pharmaceutique en Europe et l'accès des patients aux médicaments

Meeting with Alin Mituța (Member of the European Parliament, Shadow rapporteur)

22 Sept 2022 · School Scheme

Meeting with Antonius Manders (Member of the European Parliament)

13 Sept 2022 · Pharmaceutical strategy

Meeting with Jens Gieseke (Member of the European Parliament)

7 Sept 2022 · Austausch zur Europapolitik

Meeting with Andreas Glück (Member of the European Parliament)

7 Sept 2022 · Pharma Strategy

Meeting with Stéphane Séjourné (Member of the European Parliament)

1 Sept 2022 · Propriété intellectuelle (équipe)

Meeting with Nicolás González Casares (Member of the European Parliament, Shadow rapporteur)

21 Jun 2022 · rare cancers

Meeting with Nicolás González Casares (Member of the European Parliament, Shadow rapporteur)

30 May 2022 · Medicines

AbbVie warns EU pharmaceutical reforms risk undermining innovation

27 Apr 2021
Topic — EU revision of pharmaceutical regulations to improve medicine access and innovation.
Message — AbbVie supports efficient regulatory frameworks and faster assessments but opposes linking intellectual property incentives to market placement requirements or R&D cost disclosure. They argue regulatory incentives should not address availability issues caused by member state policies.123
Why — This would preserve their intellectual property protections and avoid cost-based pricing pressures.45
Impact — Patients in smaller EU markets lose if companies avoid launches there.6
Read full response

Response to Revision of the EU legislation on medicines for children and rare diseases

6 Jan 2021

As an innovative biopharmaceutical company with over 11.000 employees in the EU, AbbVie supports the Commission’s aims to develop more medicines for unmet needs, speed access to new therapies for all EU citizens, and ensure the maximum benefits from scientific and technological advances. AbbVie supports initiatives to accelerate orphan and paediatric development such as dedicated research funding for academia and SMEs, efficient clinical trial development and accelerated regulatory assessments. We are, however, concerned that amending the orphan and paediatric regulations to restrict rewards/incentives as proposed in the IIA will not achieve the Commission’s goals but may in fact lead to unintended negative consequences. AbbVie urges the Commission to consider non-legislative measures to stimulate priority product development, to recognise the complexities of orphan and paediatric development, and to reflect on the limitations of linking market access to incentives. Overall, the Regulations have been extremely successful in stimulating the development of new orphan and paediatric treatments. Before considering legislative action that could potentially threaten this European success story, the Commission should assess the impact of recent non-legislative measures that may already address its concerns. For example, Commission Guideline ENTR/6283/00 and Commission Notice 2016/C424/03 prevent sub-setting common diseases into orphan diseases unless the medicine does not work on the larger population. In paediatrics, the 2015 class waiver decision drove a significant increase in PIPs and product development, but it is too early to assess impact. Multiple initiatives in the 2018 EC/EMA Paediatric Action Plan are also still in progress. Proposals to restrict paediatric and orphan rewards/incentives to a limited set of unmet needs do not consider the complexities of discovery and development. Paediatric R&D is challenged practically by the difficulties of recruiting patients, and scientifically by a lack of basic science. The current Regulation recognises this by balancing obligations and rewards. Likewise, development in rare cancers often proceeds via indication extension, where risky R&D generates evidence to show that a known molecule can be beneficial to patients with other rare cancers. Reducing market exclusivity for follow-on orphan indications or introducing a cumulative prevalence test for orphan incentives could make R&D in rare cancers unsustainable. This would be detrimental to patients and at odds with Europe’s “Beating Cancer” ambition. Overall, reducing or restricting incentives will not attract more paediatric and orphan R&D, however, developing additional rewards for specific priority unmet needs could be a way forward. Finally, while the Regulations stimulated innovation, access remains a challenge due to complex and intertwined national pricing and reimbursement procedures. In fact, the Commission-sponsored Technopolis study concluded that access inequalities can “only be addressed by [the Orphan] Regulation to a very limited extent, as a substantial part of the observed unevenness stems from national policies and decision-making processes”. Access delays can be traced to many factors, e.g. differences in medical practice, speed of P&R negotiations, external reference pricing, and different HTA requirements. As such, proposals to link incentives to marketing of products in most/all member states place a disproportionate burden on manufacturers and are unlikely to improve access. Therefore, no legislative changes of this type should be proposed before the root causes of access delays are fully understood. In summary, in its desire to promote R&D in areas of unmet need the Commission must avoid endangering the substantial benefits that the Regulations currently bring to patients and research. AbbVie looks forward to working with all stakeholders to improve the lives of patients with unmet needs.
Read full response

Meeting with Alina-Stefania Ujupan (Cabinet of Executive Vice-President Margrethe Vestager)

24 Nov 2020 · Pharmaceutical innovation and research in Europe

AbbVie warns against eroding IP and mandatory drug launches

7 Jul 2020
Topic — European Commission consultation on the supply of affordable and innovative medicines.
Message — Maintain Europe’s pharmaceutical IP system and ensure no erosion of incentives or data exclusivity. Reject mandatory launch requirements and price transparency because they only increase complexity and unintended impacts. Develop tailored incentives for unmet needs and prioritise the EU Health Data Space.123
Why — Preserving intellectual property rights and price confidentiality protects their revenue and R&D model.4
Impact — Public health budgets and taxpayers lose the potential cost-savings from transparent pricing.5
Read full response

Meeting with Christine Schneider (Member of the European Parliament)

25 May 2020 · Gesundheitspolitische Themen

Response to Europe’s Beating Cancer Plan

3 Mar 2020

AbbVie welcomes the EU Beating Cancer Plan. As a highly focused research-driven biopharmaceutical company, AbbVie targets specific difficult-to-treat diseases in areas of high unmet need where we can leverage our core R&D expertise to advance science. Oncology is one of our main research priorities, we would like to provide constructive suggestions on how the EU can make progress in beating cancer. We call on the Commission and Member States to agree on good practice for prevention, early diagnosis and screening, both for cancers and viral infections that lead to cancer, and to monitor progress via the bi-annual State of Health report. For example, the hepatitis C virus (HCV) is strongly linked to hepatocellular carcinoma, the most common type of primary liver cancer in adults. Treatments are available that can cure HCV, hence the need for screening, diagnosing and linking HCV patients to care, to eliminate the virus and the cancer it causes by 2030. We also call for a clear understanding of diagnosis targets by cancer type – realising that staging is not considered appropriate in certain cancers including some blood cancers. We call on the EU to maintain its world class regulatory and intellectual property system – including incentives for rare and paediatric diseases – as it is a key enabler for medicine developers to continue the research necessary to create innovative cancer therapies. Critical unmet needs remain, and it is important for the EU to continue using a tool, such as the Orphan Medicinal Product Regulation, that has led to substantial investment in R&D and has delivered effective treatments for rare cancers. While as an individual company, AbbVie tries to engage authorities early to allow them to react to scientific progress, patient access can only be enhanced through a systems approach. AbbVie supports the development of a High-Level Forum on Access to Health Innovation. This ought to be a truly collaborative, ongoing and multi-stakeholder engagement between the European Commission, national governments, HTA bodies, regulators, payers, HCPs, patients and the industry to enable regulatory, healthcare technology assessment and reimbursement processes to keep abreast of the pace of innovations in cancer, and to find solutions to make them available for all. Enhanced collaboration must also enable alignment on evidence generation plans throughout the drug development process. With regard to support for patients, carers and survivors, pockets of excellence exist throughout Europe. To ensure that all European patients profit from them, we call on the European Commission and Member States to collect best practice examples and put them together in a “patient support gold standard”. This should also encompass stratified follow-up support for patients that might be in remission, relapse, have their condition progress or metastasise or receive a secondary cancer diagnosis. Implementation should be monitored via the State of Health in the EU report. The European Health Data Space, through EU registries and data platforms, provides the opportunity to analyse multiple large data sets at the same time. Registries and data platforms need to be interoperable, and the data should be routinely and consistently collected across clinical and research settings, capturing health outcomes (including patient experience), as well as basic reporting of incidence, mortality, survival and treatment. Robust data sets allow for further research and to ensure that clinical practice informs R&D processes to foster enhanced patient care – such as seen through the IMI HARMONY project. A robust governance framework is required to ensure patient data remains confidential and secure, whilst also enabling innovation that advances clinical development through ethical access – by both public and private researchers – to data sets, that can inform decision-making in reimbursement and clinical practice to benefit long-term health outcomes.
Read full response

Meeting with Tom Tynan (Cabinet of Commissioner Phil Hogan)

24 May 2018 · Business discussion

Meeting with Leila Fernandez-Stembridge (Cabinet of Commissioner Pierre Moscovici)

27 Mar 2018 · IP regime generic manufacturers in the pharmaceutical industry

Meeting with Nele Eichhorn (Cabinet of Vice-President Cecilia Malmström) and Portland PR Europe Limited

26 Mar 2018 · SPC waiver